Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziltivekimab for coronary plaque burden after acute myocardial infarction
NL-OMON60616Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) and coronary arteriosclerosis comparing Ziltivekimab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Primary: Change in percent atheroma volume. Started Apr 2026; status: recruiting.
02
Drugs
ziltivekimab
03
Conditions
myocardial infarction (MI)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON60616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60616.